Elevated expression of the tyrosine phosphatase SHP-1 defines a subset of high-grade breast tumors by Insabato, Luigi et al.
Fax +41 61 306 12 34
E-Mail karger@karger.ch
www.karger.com
 Clinical Translational Research 
 Oncology 2009;77:378–384 
 DOI: 10.1159/000276765 
 Elevated Expression of the Tyrosine 
Phosphatase SHP-1 Defines a Subset of 
High-Grade Breast Tumors 
 Luigi Insabato a    Ivano Amelio d    Maria Quarto b    Antonella Zannetti e    
Fabio Tolino d    Gaia de Mauro d    Laura Cerchia d    Patrizia Riccio c    
Daniel Baumhoer f    Gerolama Condorelli c    Luigi Terracciano f    
Vittorio de Franciscis d 
 a  Biomorphological and Functional Science, Anatomic Pathology Section, Faculty of Medicine,  b  Dipartimento 
Scienze Fisiche,  c  Dipartimento di Biologia e Patologia Cellulare e Molecolare, Università degli Studi di Napoli 
Federico II,  d  Istituto di Endocrinologia ed Oncologia Sperimentale, e  e  Istituto di Biostrutture e Bioimmagini, CNR, 
 Napoli , Italia;  f  Institute of Pathology, University Hospital,  Basel , Switzerland 
estrogen receptor, while it was weakly associated with Bcl-2 
expression.  Conclusions: Levels of SHP-1 were correlated 
with conventional pathologic parameters of tumor aggres-
siveness and were associated with reduced patient survival, 
suggesting that elevated expression of SHP-1 is a common 
molecular abnormality in a defined subset of breast tumors 
and might be used in routine diagnosis to identify patients 
with high-risk tumors.  Copyright © 2010 S. Karger AG, Basel 
 Introduction 
 Tyrosine phosphorylation through the concerted ac-
tion of protein tyrosine kinases and protein tyrosine phos-
phatases (PTPs) regulates the activity of key proteins in-
volved in cell proliferation, differentiation and the cell 
cycle. Consequently, aberrant activation of protein tyro-
sine kinases by somatic mutation, amplification and/or 
overexpression is a frequent event in human tumors. In-
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 Abstract 
 Objectives: Protein tyrosine phosphatases are key regula-
tors of intracellular signaling that contribute to determining 
cancer cell growth, which thus makes them attractive tar-
gets for therapeutic and diagnostic agents. SHP-1 phospho-
tyrosine phosphatase is rarely expressed in epithelial tumor 
cells, but expression has been found in several breast cancer 
cell lines and tumors. To determine the potential signifi-
cance of SHP-1 as a prognostic marker in the clinical setting, 
we examined SHP-1 protein expression in breast tumors. 
 Methods: We analyzed SHP-1 expression by immunohisto-
chemistry in a breast tissue microarray composed of 2,081 
cores, either alone or in combination with known prognostic 
markers.  Results: Our data showed that SHP-1 expression 
was confined to a well-defined subset of high-grade tumors 
characterized by unique biological parameters. SHP-1 ex-
pression correlated directly with expression of the tyrosine 
kinase receptor HER-2 and inversely with expression of the 
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creased tyrosine phosphatase activity has been implicated 
in human breast cancer and is regarded as an important 
diagnostic parameter  [1] . PTPs do not merely attenuate 
kinase signaling but may directly determine cancer cell 
growth, which thus makes them interesting targets for 
therapeutic and diagnostic agents. A paradigmatic exam-
ple is the SH2-containing tyrosine phosphatase SHP-2, 
which is implicated in various solid cancers and is found 
to be mutated in several leukemias  [2, 3] . SHP-2 and its 
homolog, SHP-1, are non-transmembrane phosphotyro-
sine phosphatases that play a key role in regulating cyto-
kine/protein tyrosine kinase-mediated signaling and are 
counted among the molecular determinants that regulate 
cell proliferation in normal and neoplastic cells  [3–6] . 
SHP-1 (previously named SHPTP1, HCP or PTP1C) is 
predominantly expressed in hematopoietic cells and like-
ly serves as a negative regulator of most hematopoietic-
specific signaling systems  [7–12] . In tumors of epithelial 
origin, little is known about the expression of SHP-1  [13, 
14] . However, the presence of high levels of SHP-1 mRNA 
in some breast cancer cell lines and primary breast tumors 
 [13] suggests an active function for SHP-1 in these tumors. 
On the other hand, in the human breast cancer cell line 
MCF-7, a role for SHP-1 as a positive regulator of cell death 
has been suggested. Indeed, the resistance of MCF-7 cells 
to trichostatin A-induced apoptosis is decreased by stable 
overexpression of SHP-1, likely by a mechanism that in-
volves the phosphatidylinositol 3-kinase pathway  [15] . A 
function of SHP-1 as a positive regulator of cell death is 
further supported by the finding that it may act as a TrkA 
phosphatase, balancing the level of TrkA-induced cell 
survival in cultured neurons and PC12 cells  [16] .
 To evaluate the prognostic role of SHP-1 in breast can-
cer, we analyzed SHP-1 protein expression in the clinical 
setting, using a large number of breast tumors in tissue 
microarray (TMA) format. TMA data were compared 
with molecular features, demonstrating that SHP-1, 
which is not expressed in normal breast tissues, is consis-
tently present in a subset of high-grade breast cancer. 
High expression levels of SHP-1 correlate significantly 
with tumor aggressiveness, indicating that SHP-1 protein 
might help to make a more accurate prediction of pro-
gression of the disease.
 Materials and Methods 
 Breast Cancer TMA and Immunohistochemistry 
 Four-micrometer-thick sections of TMA blocks were trans-
ferred to an adhesive-coated slide system (Instrumedics Inc., 
Hackensack, N.J., USA) supporting the cohesion of 0.6-mm array 
elements on glass. Standard indirect immunoperoxidase proce-
dures were used for immunohistochemistry. After pretreatment 
with proteinase K (Dako, Carpinteria, Calif., USA), the anti-SHP-
1 antibody (ab2020; Abcam plc, Cambridge, UK) was used at a 
dilution of 1: 500. A diaminobenzidine chromogen was used. Nu-
clei were counterstained with hematoxylin. The percentage of 
positive neoplastic cells was estimated. For SHP-1, we arbitrarily 
used 20% as a cutoff of positivity for the purpose of statistical 
analysis. The scoring was performed by a single pathologist (L.I.). 
All slides from all tumors were reviewed by 1 of 2 pathologists to 
define the histologic grade according to Elston and Ellis  [17] and 
the histologic tumor type.
 Cells and Culture Conditions 
 MCF-7 and MCF-7 siRNA-SHP-1 cell lines were grown in 
DMEM (Invitrogen Corporation, San Diego, Calif., USA) supple-
mented with 5% fetal bovine serum (Invitrogen), 2 m M  L -gluta-
mine, 1% penicillin/streptomycin, 3.75 ng/ml epidermal growth 
factor (Sigma, St. Louis, Mo., USA), 10   g/ml insulin and 500 ng/
ml hydrocortisone. T47D and MDA-MB-231 cell lines were grown 
in RPMI-1640 (Invitrogen) supplemented with 10% fetal bovine 
serum, 2 m M  L -glutamine and 1% penicillin/streptomycin. The 
SKBr-3 cell line was grown in DMEM supplemented with 10% 
fetal bovine serum, 2 m M  L -glutamine and 1% penicillin/strepto-
mycin.
 MCF-7 siRNA-SHP-1 is an MCF-7 derivative cell clone stably 
expressing the shRNA for SHP-1 as an insert into pcDNA 6.2-
GW/miR (Invitrogen). The sequence of the siRNA that specifi-
cally knocks down expression of human SHP-1 is as follows: 5  -
TACTCCACCAGCTCTGTCAGA-3  . This sequence is followed 
by 19 nucleotides derived from miR-155 to form a terminal loop 
and sense target sequence nucleotides 1–8 and 11–21 (nucleotides 
9 and 10 are removed to form a short internal loop in the mature 
miRNA, which results in more efficient knockdown). MCF-7
siRNA- SHP-1 cells stably expressing miRNA were established by 
selection with medium containing 5 ng/ml blasticidin S HCl (In-
vitrogen). The medium was renewed every 3 days. After 2 weeks, 
resistant colonies were trypsinized, isolated and characterized. 
 Synchronization and Cell Cycle Analysis 
 Cells were rendered quiescent by serum deprivation for 24 h 
and then stimulated to re-enter the cell cycle by the addition of 
10% serum. When 70–80% confluence was reached, cells were 
detached with trypsin and fixed with methanol overnight. Sam-
ples were resuspended in 0.5 ml of PBS and stained with propid-
ium iodide in the dark for 30 min, and the DNA content was mea-
sured by fluorescence-activated cell sorting on a Becton-Dickin-
son FACScan flow cytometry system. The data were analyzed 
using Mod-FIT software.
 Protein Isolation from Human Breast Tissues 
 Breast tissue specimens   were collected from surgical mastec-
tomy of 25 patients affected   by human breast cancer. All of our 
studies were carried out after fulfilling all the required ethical 
standards of the responsible institution (Committee on Human 
Experimentation). Tissues were minced with a mortar and pestle 
(Morgan Technical Ceramics, Waldkraiburg, Germany) and then 
homogenized in 1 ml   of harvest buffer [50 m M Tris-HCl (pH 7.4), 
150 m M NaCl, 5 m M EDTA, 1 m M sodium orthovanadate, 1% 
Nonidet P40 (Sigma)] containing protease inhibitor   cocktail 
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(Roche Diagnostic, Montreal, Canada), with a Dounce tissue 
grinder (Wheaton, Millville, N.J., USA). Solubilized proteins were 
incubated for 30 min on ice. After   centrifugation at 10 000  g for 
30 min at 4 ° C, supernatants   were collected.
 Immunoblot Analysis 
 Protein concentrations from tissues (100–200 mg each) or cell 
extracts were determined by Bradford assay using bovine serum 
albumin as standard. Thirty micrograms of each sample of pro-
tein extracts were prepared in Laemmli sample buffer, denatured 
for 5 min at 100 ° C, then subjected to SDS-PAGE. Gels were elec-
troblotted into polyvinylidene difluoride membranes (Millipore 
Co., Bedford, Mass., USA), and the signals were detected with the 
indicated primary antibodies and peroxidase-conjugated second-
ary antibodies using an enhanced chemiluminescence system 
(Amersham-Pharmacia Biosciences Ltd.). Primary antibodies 
used were anti-SHP-1 (C-19; Santa Cruz Biotechnology, Santa 
Cruz, Calif., USA) and anti-  -actin (Sigma). Secondary antibod-
ies used were anti-mouse (Amersham-Pharmacia Biosciences) 
and anti-rabbit (Santa Cruz Biotechnology).
 [ 3 H]Thymidine Incorporation Assay 
 The plasmids pCEFL-hemagglutinin (HA), pCEFL-HA SHP-
1(wildtype) and pCEFL-HA SHP-1 Cys453 to Ser mutant (C/S), 
containing the SHP-1 gene, fused to the HA epitope. The mutated 
human SHP-1 (C/S) is still able to bind substrates, but it is cata-
lytically inactive. Transient transfections (15   g of each plasmid) 
were carried out in 100-mm cell culture dishes with Lipofectamine 
2000 reagent (Life Technologies Inc.), and cells were grown in the 
absence of serum for 5 h. After 16 h, 50,000 cells were replated in 
triplicate in 24-well tissue culture dishes. For each transfection, a 
cell aliquot was lysed and protein was analyzed by immunoblot 
with anti-HA antibodies; equal transfection efficiency was con-
firmed (not shown). Six, 30 and 54 h after replating, cells were 
treated with 4-hour pulses of 1   Ci/ml [ 3 H]thymidine (45 Ci/
mmol; Amersham-Pharmacia Biosciences) added in complete 
growth medium and incubated at 37 ° C. At the end of each pulse, 
dishes were placed on ice, and cells were washed with ice-cold 
PBS, 5% trichloroacetic acid and, finally, with methanol. Cells 
were then dissolved in 0.3  N NaOH, and [ 3 H]thymidine incorpo-
ration was analyzed by a Beckman LS 1701 Liquid Scintillation 
Counter.
 Statistics 
 The associations of some molecular features with SHP-1 ex-
pression were evaluated using the   2 test. To investigate the effect 
of high expression of SHP-1 on patient prognosis, we performed 
a univariate survival analysis using the Kaplan-Meier method 
and a log-rank test. Statistical analysis was performed using Stata 
software (Stata Corp., College Station, Tex., USA).
 Results 
 SHP-1 Expression in Human Breast Tumors 
 We first determined the expression levels of SHP-1 in 
human breast cancer specimens from 4 patients for whom 
the corresponding adjacent normal tissue was available. 
None of the patients were receiving medical treatment at 
the time of the operation. Immunoblot analysis showed 
that SHP-1 was never expressed in normal breast, while 
it was expressed at various intensities in the adjacent 
breast tumor samples from 3 patients ( fig. 1 a). 
 We then analyzed the frequency of SHP-1 expression 
in breast tumors by using a breast cancer TMA composed 
of 2,081 samples (2,048 tumors and 33 normal breast con-
trols)  [18] . The large majority of tumors belonged to the 
ductal (1,426 cores) and lobular carcinoma (297 cores) 
histotypes. In line with the results obtained by immuno-
blot, all epithelial cells from normal breast controls were 
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 Fig. 1. SHP-1 protein expression in human 
breast tissues.  a SHP-1 expression levels 
were analyzed by immunoblot with anti-
SHP-1 antibody in different breast tumors 
(T) or adjacent normal tissue (N) obtained 
from 4 patients (Pt). Equal loading of pro-
tein was confirmed using anti-  -actin an-
tibody.  b, c Immunoperoxidase staining 
for SHP-1.  b Representative TMA with 
negative and positive cores for SHP-1. 
Original magnification  ! 40.  c High-grade 
breast carcinoma with strongly positive 
tumor cells. Mitotic activity is evident (ar-
row). Original magnification  ! 400. 
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immunohistochemically negative for SHP-1, while a group 
of tumors showed cytoplasmic positivity ( table 1 ). 
 Since nuclear SHP-1 staining was observed in only a 
small fraction of the SHP-1-positive samples (2.2%), only 
cytoplasmic staining was considered positive in this set-
ting ( fig. 1 b). Overall, approximately 7.2% of all breast tu-
mors analyzed showed positive staining for SHP-1. The 
ductal histotype, which constituted 68% of the TMA, had 
a similar distribution (8.3% of cores positive for SHP-1), 
while SHP-1-positive staining in the lobular carcinoma 
cores was much rarer, with only 2.0% of such tumors ex-
pressing SHP-1 ( table 1 ), thus suggesting that SHP-1 ex-
pression is not homogenously distributed among all types 
of breast cancers.
 SHP-1 Defines a Subset of High-Grade Breast Cancers 
 In order to test the significance of SHP-1 expression in 
determining the biological behavior of the disease, we 
analyzed the relationship between SHP-1 expression and 
3 common parameters of aggressiveness, i.e. histological 
grade  [17] and expression levels of the HER-2 gene and 
the estrogen receptor (ER). As shown in  table 2 , 11% of 
high-grade tumors (G3) expressed SHP-1, while only 5% 
of low-grade tumors (G1) were positive for this phospha-
tase. In addition, 18% of the tumors that expressed high 
levels of HER-2 also expressed SHP-1. Accordingly, SHP-
1 was expressed in 13% of tumors characterized by the 
absence of a functional ER (ER-negative tumors). 
 Furthermore, by introducing a cutoff to exclude values 
less than 10%, we tested the correlation between SHP-1 
expression and the Ki67 labeling index, a marker of cell 
proliferation that was recently analyzed on the same 
TMA  [18] . The Ki67 labeling index was shown to be 
strongly associated with high-grade tumors and was 
strongly linked to poor prognosis in this same cohort 
 [18] . Here, we found that, although expression of SHP-1 
correlates with molecular indicators of aggressiveness 
(see above), it did not correlate with high Ki67 (not 
shown). Taken together, these results indicate that high 
expression of SHP-1 identifies a subset of high-grade 
breast tumors, as assessed by independent parameters.
 High Levels of SHP-1 Expression Are Associated with 
the Absence of Bcl-2 and the Presence of p16/Ink4a. 
 In order to further characterize tumors expressing 
high levels of SHP-1, we analyzed expression levels of 2 
key proteins involved in cell survival and proliferation, 
Table 1. Staining levels of SHP-1 in the different breast cancer 
histotypes of the TMA
Tumor histotype SHP-1 staining Total
negative positive
Adenocystic carcinoma 1   0 1
Apocrine carcinoma 13   1 14
Atypical medullary carcinoma 8   1 9
Carcinosarcoma 2   0 2
Clear cell carcinoma 8   4 12
Cribriform carcinoma 58   2 60
Ductal carcinoma 1,307 119 1,426
Histocytic carcinoma 2   0 2
Lipid-rich carcinoma 1   1 2
Lipid-rich or histioc 2   0 2
Lobular carcinoma 291   6 297
Medullary carcinoma 53   2 55
Metaplastic carcinoma 5   0 5
Mucinous carcinoma 65   2 67
Neuroendocrine carcinoma 1   1 2
Papillary carcinoma 23   4 27
Signet ring carcinoma 0   1 1
Small cell carcinoma 2   0 2
Lobular carcinoma 47   5 52
Ductal carcinoma in situ 9   0 9
Lobular carcinoma in situ 1   0 1
Total 1,932 149 2,081
Normal breast 33   0 33
Results for negative and positive SHP-1 expression were ob-
tained by grouping negative and positive SHP-1 staining as de-
scribed in Materials and Methods.
Table 2. Association between staining of SHP-1 and 3 clinical pa-
rameters: tumor grade, HER-2 overexpression and ER status
SHP-1 staining p value
total, n positive, %
Tumor grade G1
G2
G3
532
866
667
5
6
11
<0.001
HER-2 0+1
2
3
1,637
61
197
6
11
18
<0.001
ER negative
positive
438
1,480
13
5
<0.001
For each parameter (tumor grade, HER-2 staining intensity 
and ER status), the total number of tumors and the percentage of 
tumors that stained positive for SHP-1 are indicated. The p values 
were calculated with Stata software.
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i.e. Bcl-2, which is involved both in counteracting apop-
tosis and cell cycle control  [19] , and the tumor suppressor 
gene, p16/Ink4a, which acts by inhibiting the phosphory-
lation of retinoblastoma protein family members  [20] . As 
shown in  table 3 , expression of SHP-1 was significantly 
higher in tumors with absent or low Bcl-2 expression
(p = 0.01) and in tumors expressing p16/Ink4a (p = 
0.001).
 Survival Analysis 
 We further analyzed the relationship between high ex-
pression of SHP-1 and patient survival. As expected, sur-
vival estimates in the whole TMA ( fig. 2 a) decreased with 
increasing tumor grade, with a value of 50% for overall 
survival at approximately 86 months for high-grade tu-
mors (p value = 0.05). Values and trends for survival of 
patients with tumors positive for SHP-1 staining ( fig. 2 b; 
p value = 0.022) were similar to those of high-grade tu-
mors, reaching a value of 50% for overall survival at 100 
months, with a similarly shaped curve, while the control 
population (tumors negative for SHP-1 staining) reached 
50% survival at 145 months. A similar trend for survival 
was obtained if only the ductal histotype was analyzed, 
as expected with the high frequency of this tumor type in 
the TMA (data not shown).
 Expression of SHP-1 Does Not Promote Cell 
Proliferation 
 Given the lack of correlation of SHP-1 levels with the 
Ki67 labeling index as a measure of cell proliferation (see 
above), we determined the ability of SHP-1 to promote 
DNA synthesis in breast cancer-derived stable cell lines. 
SHP-1 was expressed in only 2 of the 4 cell lines analyzed, 
i.e. MCF-7 and SKBr-3, whilst T47D and MDA-MB-231 
were negative ( fig. 3 a).
 As shown in  figure 3 b, forced expression of SHP-1 
(wildtype) in SHP-1-negative T47D cells had low inhibi-
tory effects on thymidine incorporation (of less than 10% 
at 54 h), while inhibition of endogenous SHP-1 activity in 
MCF-7 cells by expression of the interfering mutant SHP-
1 (C/S) had no effect ( fig. 3 c). Likewise, using an MCF-7 
derivative cell line (MCF-7 siRNA-SHP-1) in which the 
expression of SHP-1 is reduced by stable expression of a 
specific siRNA (not shown), the percentage of cells in S 
phase increased by around 5% ( fig. 3 d). These data indi-
cate that SHP-1 is unlikely to be functionally involved in 
determining the proliferation rate of those tumors in 
which it is expressed.
0
0
0.25
0.50
0.75
1.00
50 100 150 200
Time (months)a
Tumor grade = 1
Tumor grade = 2
Tumor grade = 3 p < 0.05
0
0
0.25
0.50
0.75
1.00
50 100 150 200
Time (months)b
SHP-1 = negative
SHP-1 = positive p = 0.022
 Fig. 2. Survival analysis.  Survival analysis of the TMA cohort, 
showing Kaplan-Meier curves according to tumor grade ( a ) and 
SHP-1 expression ( b ). 
Table 3. Association between SHP-1-positive tumors and Bcl-2 or 
p16 expression in TMA samples
SHP-1 staining
total, n positive, 
%
p value
Bcl-2 0+1
2+3
311
1,551
12
7
<0.01
p16 negative
positive
1,235
634
6
10
<0.001
For each parameter (Bcl-2 and p16 expression intensity), the 
total number of tumors and the percentage of tumors that stained 
positive for SHP-1 are indicated. The p values were calculated 
with Stata software.
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 Discussion 
 In the present study, we used a TMA-based approach 
to investigate the expression of the tyrosine phosphatase 
SHP-1 in human breast cancer in association with sev-
eral clinical and biological parameters. Our data demon-
strate that SHP-1 protein is expressed in tumors whilst it 
is absent in normal breast tissue, indicating that SHP-1 
expression is frequently deregulated in breast tumors. 
They further indicate that high expression of SHP-1 iden-
tifies a particular subset of breast tumors. Tumors ex-
pressing SHP-1 were in fact predominantly of the ductal 
type and were characterized by aggressive biological be-
havior. Accordingly, high expression of SHP-1 correlated 
directly with high HER-2 expression and inversely with 
ER expression. Importantly, high SHP-1 expression was 
significantly associated with reduced survival. Further-
more, by using independent measurable parameters pres-
ent in our TMA records  [18] , we assigned SHP-1-express-
ing tumors to a rather homogeneous subset of high-grade 
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 Fig. 3. SHP-1 expression does not affect thymidine incorporation 
in breast cancer cell lines.  a  SHP-1 expression levels were analyzed 
by immunoblot with an anti-SHP-1 antibody in exponentially 
growing MCF-7, SKBr-3, T47D and MDA-MB-231 breast carci-
noma cell lines. Equal loading of samples was confirmed on the 
same blots with anti-  -actin antibody.  b T47D cells were trans-
fected with the vector pCEFL-HA and with pCEFL-HA SHP-
1(wildtype; wt), and [ 3 H]thymidine incorporation was monitored 
(as described in Materials and Methods) at the indicated times.
 c MCF7 cells were transfected with pCEFL-HA SHP-1 (wildtype; 
wt) and with pCEFL-HA SHP-1 C/S, and [ 3 H]thymidine incorpo-
ration was monitored at the indicated times. Values are the means 
of triplicate reactions, with vertical bars representing the SD.
 d MCF-7 and MCF-7 siRNA-SHP-1 cells were analyzed by optical 
cytofluorimetry analysis to determine the percentage of cells in 
the G1, S and G2 phases of the cell cycle. The coefficient of varia-
tion of the peaks, which represents the ratio of the standard de-
viation and average values, was measured to confirm the signifi-
cance of measurements and was 4.5% for the MCF-7 cell line and 
5.2% for the MCF-7 siRNA-SHP-1 cell line. Values are results of a 
representative experiment. 
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tumors. Indeed, we show that, in contrast to the large ma-
jority of high-grade tumors in the TMA (data not shown), 
those expressing SHP-1 are weakly associated with high 
Bcl-2 expression. Moreover, this subset is characterized 
by the frequent expression of the tumor suppressor gene 
p16/Ink4a.
 Our results indicate that even though it seems unlike-
ly that SHP-1 has a functional involvement in determin-
ing the highly malignant phenotype of tumors in which 
it is expressed, some of the effects that have previously 
been reported to be induced by SHP-1 in the breast cell 
line MCF-7 are reflected in the subset of high-grade breast 
tumors expressing SHP-1. Considering that SHP-1 gener-
ally opposes oncogenic signaling pathways  [14] , it is plau-
sible that the overexpression of SHP-1 in tumors of ad-
vanced stage and poor clinical outcome may act as a com-
pensatory and opposing mechanism to more pronounced 
oncogenic signaling.
 Although SHP-1 seems to be implicated at the molec-
ular level in regulating cell signals in hematopoietic cell 
lines, little is known about its involvement in cancer. 
SHP-1 protein and mRNA levels are downregulated in 
various leukemia and lymphoma cell lines, but not in ep-
ithelial cell lines, including breast cancer cell lines, in 
which SHP-1 levels are normal or overexpressed  [13, 14] . 
To our knowledge, this is the first study on a large group 
of solid tumors demonstrating that elevated expression of 
SHP-1 may serve as a marker of poor prognosis for a sub-
set of high-grade breast cancers characterized by unique 
biological parameters and with a poor clinical course that 
makes this set of tumors of interest for therapeutic ap-
proaches.
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